Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are known to provide additional and complementary gene variant data compared to cell free DNA (cfDNA) alone1,2
Combined assessment of both analytes can provide additional and complementary information that could inform personalised treatment decisions and is called a dual analysis approach. This has the potential to make substantive improvements in patient care.
CelLBxHealth has developed a single blood tube, next-generation sequencing (NGS) workflow that enables highly sensitive dual analysis of CTC-DNA and (cfDNA) across a large gene panel. ctDNA exists as part of cfDNA, so this protocol ensures that ctDNA is accounted for in the analysis.
By integrating this DNA dual analysis workflow, CelLBxHealth aims to advance research-use applications in tracking tumour evolution, monitoring treatment response, and detecting drug resistance, providing deeper insights into cancer biology through liquid biopsy analysis.
DNA dual analysis has the potential to identify a broader range of clinically actionable biomarkers for the treatment of patients in multiple cancer types. Molecular profiling of cfDNA and CTC-DNA could help the clinician track tumour evolution to inform treatment decisions, monitor response to treatment, identify drug resistance mechanisms and identify disease progression earlier1-6.
Find out more about the use of the Parsortix system for dual CTC-DNA and cfDNA analysis
Additional resources related to NGS
Posters
Unlocking the potential of liquid biopsy in glioblastoma: a extensive evaluation of circulating biomarkers
ANGLE Europe Limited, Guildford, UK, published at SNO Meeting 2025
References:
1. Keller, L. & Pantel, K. Nat. Rev. Cancer 19, 553–567 (2019).
2. Markou, A. N. et al. Cancers 15, 1877 (2023).
3. Kong, S. L. et al. Front. Oncol. 11, 698551 (2021).
4. Ntzifa, A., Kotsakis, A., Georgoulias, V. & Lianidou, E. Cancers 13, 2736 (2021).
5. Gorges, K. et al. Cancers 11, (2019).
6. Wishart, G, et al. Curr. Issues Mol. Biol. 46, 773–787 (2024).
For Research Use Only. Not For Use In Diagnostic Procedures.